VIR Biotechnology
biotech company
VIR Nasdaq
SEC CIK 1706431
Follow VIR Biotechnology
Weekly email: filings, results
Net income
−$96.3M
+41% vs same quarter last year
EPS, diluted
−$0.57
+51.3% vs same quarter last year
Operating cash flow
−$106.1M
+36.7% vs same quarter last year
Operating income
−$104.7M
+39.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $68.6M | −$438M |
| FY24 | $74.2M | −$522M |
| FY23 | $86.2M | −$615.1M |
| FY22 | $1.6B | $515.8M |
| FY21 | $1.1B | $528.6M |
| FY20 | $76.4M | −$298.7M |
| FY19 | $8.1M | −$174.7M |
| FY18 | $10.7M | −$115.9M |
| FY17 | $2.7M | −$69.9M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 100% | −699.2% | −638.9% |
| FY24 | 98.9% | −791.3% | −703.4% |
| FY23 | 96.8% | −794% | −713.8% |
| FY22 | 90.9% | 51.6% | 31.9% |
| FY21 | 94% | 38.4% | 48.3% |
| FY20 | 100% | −388.9% | −391.1% |
| FY19 | 100% | −2199.7% | −2159% |
| FY18 | - | −1112.6% | −1086.3% |
| FY17 | - | −3009.5% | −2579.5% |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$396.6M |
| FY24 | −$453.7M |
| FY23 | −$800.4M |
| FY22 | $1.6B |
| FY21 | −$69.4M |
| FY20 | −$197.5M |
| FY19 | −$138.6M |
| FY18 | −$102.3M |
| FY17 | −$69.1M |
| FY16 | - |
- VIR Biotechnology
- Healthcare median
Show the numbers
| Year | VIR Biotechnology | Healthcare median |
|---|---|---|
| FY25 | −638.9% | −30.6% |
| FY24 | −703.4% | −47% |
| FY23 | −713.8% | −58% |
| FY22 | 31.9% | −80.4% |
| FY21 | 48.3% | −71.8% |
| FY20 | −391.1% | −62.2% |
| FY19 | −2159% | −46.2% |
| FY18 | −1086.3% | −49.6% |
| FY17 | −2579.5% | −45.9% |
| FY16 | - | −36% |